An ethical view of the ranibizumab and bevacizumab controversy.
Packer
Samuel
S
Jampol
Lee M
LM
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D004645:Empathy; D004992:Ethics, Medical; D005128:Eye Diseases / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D000069579:Ranibizumab; D018570:Risk Assessment; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab